Engage for Psychotherapy

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Nevada, Las Vegas, NV
Psychotherapy+6 More
Engage - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Although there are an increasing number of mental health treatment adaptations for older adults, there are still a number of factors to consider when making these adaptations. Cognitive decline is one such factor that places significant burden on older adults and can interfere with traditional mental health therapies. Engage is a behavioral treatment approach that has shown to be effective in treating late life depression. We are testing the feasibility of Engage as a treatment method for late life depression in older adults with cognitive decline. Our objective is to corroborate Engage as an alternative late life depression treatment method for a sub-population of older adults with cognitive decline. Cognitive decline poses a unique mental health treatment barrier that is often over looked in younger populations. With a relatively higher prevalence of cognitive decline in older adulthood, it is imperative that we find a feasible mental health treatment program that can be effective in the presence of cognitive decline.

Eligible Conditions

  • Psychotherapy
  • Depression in Old Age
  • Executive Dysfunction
  • Mild Cognitive Impairment (MCI)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Assessed at Baseline, Week 6, Week 9, and Week 36 follow-up.

Week 36
Behavioral Activation for Depression Scale (BADS)
Hamilton Depression Rating Scale
Social Problem-Solving Inventory Revised-Short Form
World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)
Week 36
Hopkins Verbal Learning Memory Test-Revised
Iowa Gambling Task - 2nd Edition
Stroop Color-Word Interference Test
Trail Making Test A & B

Trial Safety

Trial Design

1 Treatment Group

Engage Treatment
1 of 1
Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Engage · No Placebo Group · N/A

Engage Treatment
Behavioral
Experimental Group · 1 Intervention: Engage · Intervention Types: Behavioral
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Engage
2019
N/A
~1350

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: assessed at baseline, week 6, week 9, and week 36 follow-up.

Trial Background

Prof. Brenna Renn, Assistant Professor
Principal Investigator
University of Nevada, Las Vegas
Closest Location: University of Nevada · Las Vegas, NV
Photo of las vegas  1Photo of las vegas  2Photo of las vegas  3
2004First Recorded Clinical Trial
1 TrialsResearching Psychotherapy
8 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You must be 60 years of age or older.
You are located in Las Vegas or surrounding area.
You are able to travel to the UNLV campus by yourself or with a caregiver.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.